Anlotinib Combined with Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c-MET/MYC/AXL Axis

被引：0
|
作者：
Lei, T. [1 ]
Xu, T. [2 ]
Zhang, N. [1 ]
Zou, X. [1 ]
Wei, C. [1 ]
Wang, Z. [1 ]
机构：
[1] Nanjing Med Univ, Affiliated Hosp 2, Nanjing, Peoples R China
[2] Nanjing Med Univ, Nanjing Hosp 1, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Anlotinib; Osimertinib resistance; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-70
引用
收藏
页码：S670 / S670
页数：1
相关论文
共 34 条
  • [1] Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis
    Lei, Tianyao
    Xu, Tianwei
    Zhang, Niu
    Zou, Xiaoteng
    Kong, Ziyue
    Wei, Chenchen
    Wang, Zhaoxia
    PHARMACOLOGICAL RESEARCH, 2023, 188
  • [2] Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis (vol 188, 106668, 2023)
    Lei, Tianyao
    Xu, Tianwei
    Zhang, Niu
    Zou, Xiaoteng
    Kong, Ziyue
    Wei, Chenchen
    Wang, Zhaoxia
    PHARMACOLOGICAL RESEARCH, 2023, 196
  • [3] Brigatinib, a Newly Discovered AXL Inhibitor, and Suppresses AXL Mediated Acquired Resistance to Osimertinib in NSCLC
    Lu, C.
    Han, R.
    Hu, C.
    Wu, D.
    He, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S655 - S655
  • [4] Anlotinib plus osimertinib overcomes acquired resistance to osimertinib via FGFR and EGFR signaling in non-small cell lung cancer (NSCLC)
    Zhao, Q.
    Zhu, C.
    Sun, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S1231 - S1231
  • [5] AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
    Yuichi Murakami
    Daiki Kusakabe
    Kosuke Watari
    Akihiko Kawahara
    Koichi Azuma
    Jun Akiba
    Masahiko Taniguchi
    Michihiko Kuwano
    Mayumi Ono
    Scientific Reports, 12
  • [6] AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
    Murakami, Yuichi
    Kusakabe, Daiki
    Watari, Kosuke
    Kawahara, Akihiko
    Azuma, Koichi
    Akiba, Jun
    Taniguchi, Masahiko
    Kuwano, Michihiko
    Ono, Mayumi
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [7] Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis
    Li, Yue-kang
    Ge, Fu-jing
    Liu, Xiang-ning
    Zeng, Chen-ming
    Qian, Mei-jia
    Li, Yong-hao
    Zheng, Ming-ming
    Qu, Jing-jing
    Fang, Liang-jie
    Lu, Jin-jian
    Yang, Bo
    He, Qiao-jun
    Zhou, Jian-ya
    Zhu, Hong
    ACTA PHARMACOLOGICA SINICA, 2024, : 1045 - 1057
  • [8] Targeting c-Met overexpression for overcoming acquired resistance to EGFR TKIs in NSCLC.
    Gou, Lanying
    Wu, Yi-Long
    Yang, Jinji
    Zhang, Xuchao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC
    Haratake, Naoki
    Ozawa, Hiroki
    Morimoto, Yoshihiro
    Yamashita, Nami
    Daimon, Tatsuaki
    Bhattacharya, Atrayee
    Wang, Keyi
    Nakashoji, Ayako
    Isozaki, Hideko
    Shimokawa, Mototsugu
    Kikutake, Chie
    Suyama, Mikita
    Hashinokuchi, Asato
    Takada, Kazuki
    Takenaka, Tomoyoshi
    Yoshizumi, Tomoharu
    Mitsudomi, Tetsuya
    Hata, Aaron N.
    Kufe, Donald
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 434 - 450
  • [10] Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib
    Zhu, Lei
    Chen, Zhen
    Zang, Hongjing
    Fan, Songqing
    Gu, Jiajia
    Zhang, Guojing
    Sun, Kevin D-Y
    Wang, Qiming
    He, Yong
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Sun, Shi-Yong
    CANCER RESEARCH, 2021, 81 (18) : 4822 - 4834
1234